卒中前阿司匹林使用与脑梗死体积及功能结局的关系
这项多中心MRI研究纳入5700例未接受静脉溶栓或血管内取栓的首发急性缺血性卒中患者,采用倾向评分加权分析。结果显示卒中前阿司匹林使用与梗死体积减小30%、功能独立可能性提高约30%相关,尤其在大动脉粥样硬化型及心源性栓塞型卒中中,且未显著增加出血转化风险。
要点
- 卒中前阿司匹林使用与梗死体积减小30%相关,大动脉粥样硬化型达45%。
- 心源性栓塞型中,卒中前阿司匹林使用与END发生率降低约50%相关。
- 卒中前阿司匹林使用与功能独立可能性提高约30%相关,未显著增加出血转化。
核心结论
- 卒中前阿司匹林使用与首发大动脉粥样硬化型缺血性卒中患者功能独立改善相关,可能通过减少血栓负荷降低梗死体积和/或END,且不增加出血转化风险。
研究设计与样本
- 多中心基于MRI的研究,纳入2011年5月至2014年2月连续5700例未接受静脉溶栓或血管内取栓的首发急性缺血性卒中患者。
- 采用倾向评分为基础的增强逆概率加权估计卒中前阿司匹林使用的校正效应。
主要发现
- 平均年龄67岁(女性41%),15.9%(n=907)卒中前服用阿司匹林。
- 卒中前阿司匹林使用与梗死体积减小30%相关,大动脉粥样硬化型卒中减小45%。
- 心源性栓塞型卒中中,卒中前阿司匹林使用与END发生率降低约50%相关(校正差值=-5.4%,95%CI=-8.9至-1.9)。
- 卒中前阿司匹林使用与功能独立(3个月mRS<3)可能性提高约30%相关,大动脉粥样硬化型校正差值=7.2%(95%CI=1.8至12.5),心源性栓塞型校正差值=6.4%(95%CI=1.7至11.1)。
- 大动脉粥样硬化型卒中中,卒中前阿司匹林使用与SVS出现频率减少85%相关(校正差值=-1.4%,95%CI=-2.1至-0.8,p<0.001);心源性栓塞型中与SVS体积减小约40%相关(校正差值=-0.16 cm3,95%CI=-0.29至-0.02,p=0.03)。
临床怎么用
- 对于首发缺血性卒中患者,卒中前阿司匹林使用提示可能减小梗死体积并改善功能结局,尤其在大动脉粥样硬化型及心源性栓塞型卒中。
- 卒中前阿司匹林使用未显著增加出血转化风险,但需结合个体情况评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: We investigated (1) the associations of pre-stroke aspirin use with thrombus burden, infarct volume, hemorrhagic transformation, early neurological deterioration (END), and functional outcome, and (2) whether stroke subtypes modify these associations in first-ever ischemic stroke. METHODS: This multicenter magnetic resonance imaging (MRI)-based study included 5,700 consecutive patients with acute first-ever ischemic stroke, who did not undergo intravenous thrombolysis or endovascular thrombectomy, from May 2011 through February 2014. Propensity score-based augmented inverse probability weighting was performed to estimate adjusted effects of pre-stroke aspirin use. RESULTS: The mean age was 67 years (41% women), and 15.9% (n = 907) were taking aspirin before stroke. Pre-stroke aspirin use (vs nonuse) was significantly related to a reduced infarct volume (by 30%), particularly in large artery atherosclerosis stroke (by 45%). In cardioembolic stroke, pre-stroke aspirin use was associated with a ~50% lower incidence of END (adjusted difference = -5.4%, 95% confidence interval [CI] = -8.9 to -1.9). Thus, pre-stroke aspirin use was associated with ~30% higher likelihood of favorable outcome (3-month modified Rankin Scale score < 3), particularly in large artery atherosclerosis stroke and cardioembolic stroke (adjusted difference = 7.2%, 95% CI = 1.8 to 12.5 and adjusted difference = 6.4%, 95% CI = 1.7 to 11.1, respectively). Pre-stroke aspirin use (vs nonuse) was associated with 85% less frequent cerebral thrombus-related susceptibility vessel sign (SVS) in large artery atherosclerosis stroke (adjusted difference = -1.4%, 95% CI = -2.1 to -0.8, p < 0.001) and was associated with ~40% lower SVS volumes, particularly in cardioembolic stroke (adjusted difference = -0.16 cm3 , 95% CI = -0.29 to -0.02, p = 0.03). Moreover, pre-stroke aspirin use was not significantly associated with hemorrhagic transformation (adjusted difference = -1.1%, p = 0.09). INTERPRETATION: Pre-stroke aspirin use associates with improved functional independence in patients with first-ever ischemic large arterial stroke by reducing infarct volume and/or END, likely by decreasing thrombus burden, without increased risk of hemorrhagic transformation. ANN NEUROL 2021;90:763-776.
引用
- Ryu WS, Schellingerhout D, Hong KS, et al. Relation of Pre-Stroke Aspirin Use With Cerebral Infarct Volume and Functional Outcomes. Ann Neurol. 2021. PMID: 34536234. doi:10.1002/ana.26219
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。